ObsEva (OBSV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock OBSV vs. MURA, SNYR, BTAI, MAAQ, DYAI, JATT, KZR, TRIB, MDCX, and CASIShould you be buying ObsEva stock or one of its competitors? The main competitors of ObsEva include Mural Oncology (MURA), Synergy CHC (SNYR), BioXcel Therapeutics (BTAI), Mana Capital Acquisition (MAAQ), Dyadic International (DYAI), JATT Acquisition (JATT), Kezar Life Sciences (KZR), Trinity Biotech (TRIB), Medicus Pharma (MDCX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. ObsEva vs. Its Competitors Mural Oncology Synergy CHC BioXcel Therapeutics Mana Capital Acquisition Dyadic International JATT Acquisition Kezar Life Sciences Trinity Biotech Medicus Pharma CASI Pharmaceuticals ObsEva (NASDAQ:OBSV) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of OBSV or MURA? 17.5% of ObsEva shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 2.2% of Mural Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer OBSV or MURA? In the previous week, Mural Oncology had 6 more articles in the media than ObsEva. MarketBeat recorded 6 mentions for Mural Oncology and 0 mentions for ObsEva. Mural Oncology's average media sentiment score of 0.16 beat ObsEva's score of 0.00 indicating that Mural Oncology is being referred to more favorably in the news media. Company Overall Sentiment ObsEva Neutral Mural Oncology Neutral Which has higher earnings & valuation, OBSV or MURA? Mural Oncology is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEvaN/AN/A-$58.38M-$0.92N/AMural OncologyN/AN/A-$128.51M-$8.59-0.24 Do analysts rate OBSV or MURA? Mural Oncology has a consensus price target of $12.00, suggesting a potential upside of 476.92%. Given Mural Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Mural Oncology is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is OBSV or MURA more profitable? Mural Oncology's return on equity of -107.76% beat ObsEva's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% Mural Oncology N/A -107.76%-87.57% Which has more risk & volatility, OBSV or MURA? ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500. SummaryMural Oncology beats ObsEva on 9 of the 13 factors compared between the two stocks. Get ObsEva News Delivered to You Automatically Sign up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBSV vs. The Competition Export to ExcelMetricObsEvaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.94M$833.52M$5.82B$9.76BDividend YieldN/A4.84%4.40%4.04%P/E Ratio0.001.1831.3826.05Price / SalesN/A26.35472.41122.40Price / CashN/A19.5625.7828.78Price / BookN/A6.579.526.07Net Income-$58.38M-$5.54M$3.26B$265.39M ObsEva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050MURAMural Oncology2.9491 of 5 stars$1.78-2.5%$12.00+576.1%-39.9%$30.75MN/A-0.21119SNYRSynergy CHC4.3616 of 5 stars$3.27-6.0%$10.00+205.8%+2,840.0%$30.06M$33.70M8.6140BTAIBioXcel Therapeutics4.5666 of 5 stars$4.86-14.3%$39.75+718.2%-54.2%$29.69M$2.27M-0.3990Short Interest ↓MAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+775.1%$29.49MN/A0.001DYAIDyadic International2.7654 of 5 stars$0.800.0%$6.00+654.7%-41.4%$28.77M$3.49M-4.187Gap UpJATTJATT AcquisitionN/A$1.66-3.5%N/A-43.7%$28.64MN/A0.003High Trading VolumeKZRKezar Life Sciences3.8628 of 5 stars$3.88+0.4%$9.00+132.3%-35.4%$28.37M$7M-0.4060TRIBTrinity Biotech1.437 of 5 stars$1.51-3.8%N/A-21.5%$27.98M$61.56M-0.53480Upcoming EarningsGap DownMDCXMedicus Pharma1.867 of 5 stars$2.01+0.5%$23.50+1,069.2%N/A$27.28MN/A-1.50N/ANews CoverageAnalyst ForecastGap DownHigh Trading VolumeCASICASI Pharmaceuticals3.7024 of 5 stars$2.23-1.5%$4.00+79.8%-63.4%$27.20M$28.54M-0.87180 Related Companies and Tools Related Companies Mural Oncology Alternatives Synergy CHC Alternatives BioXcel Therapeutics Alternatives Mana Capital Acquisition Alternatives Dyadic International Alternatives JATT Acquisition Alternatives Kezar Life Sciences Alternatives Trinity Biotech Alternatives Medicus Pharma Alternatives CASI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBSV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access